Evidence map›Paper›PMID 36750134›Full record

Trial reportAddiction (Abingdon, England)2023

The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.

Will Lawn, Katie Trinci, Claire Mokrysz, Anna Borissova, Shelan Ofori, Kat Petrilli, Michael Bloomfield, Zarah R Haniff, Daniel Hall, Natalia Fernandez-Vinson and 6 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Addiction (Abingdon, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04851392 (Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?), which is not on this map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04851392 nacompletednot on this map

Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?

TypeinterventionalSponsorUniversity College, LondonRan2019 to 2021Enrolled48ConditionsCannabis, Cannabis Intoxication, Cannabis Use, Cannabis DependenceArmsCannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), Cannabis with THC without CBD, Placebo cannabis
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  6. Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  7. Trial
  8. Trial
  9. Longitudinal neurocognitive trajectories in a large cohort of youth who use cannabis: combining self-report and toxicology.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Exploring causal mechanisms of psychosis risk.Neuroscience and biobehavioral reviews · 2024
    Review
  17. Review
  18. Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Will LawnDepartment of Psychology, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0002-0143-2724
Katie TrinciClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
Claire MokryszClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.ORCID 0000-0002-1970-8530
Anna BorissovaDepartment of Neuroimaging, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.
Shelan OforiClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
Kat PetrilliAddiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.ORCID 0000-0001-9801-1442
Michael BloomfieldClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
Zarah R HaniffClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
Daniel HallClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
Natalia Fernandez-VinsonClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
Simiao WangDepartment of Addictions, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.
Amir EnglundDepartment of Addictions, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.
Edward ChesneyDepartment of Addictions, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.
Matthew B WallClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
Tom P FreemanClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.ORCID 0000-0002-5667-507X
H Valerie CurranClinical Psychopharmacology Unit, Clinical Educational and Health Psychology, University College London, London, UK.
Health Data Research UK · GBKing's College London · GBUniversity College Hospital · GBHammersmith Hospital · GBUniversity of Bath · GB

Funding

Medical Research Council MR/P012728/1
6 · The paper itself

Abstract

BACKGROUND AND

aimsLong-term harms of cannabis may be exacerbated in adolescence, but little is known about the acute effects of cannabis in adolescents. We aimed to (i) compare the acute effects of cannabis in adolescent and adult cannabis users and (ii) determine if cannabidiol (CBD) acutely modulates the effects of delta-9-tetrahydocannabinol (THC).

designRandomised, double-blind, placebo-controlled, crossover experiment. The experiment was registered on ClinicalTrials.gov (NCT04851392).

settingLaboratory in London, United Kingdom.

participantsTwenty-four adolescents (12 women, 16- to 17-year-olds) and 24 adults (12 women, 26- to 29-year-olds) who used cannabis 0.5-3 days/week and were matched on cannabis use frequency (mean = 1.5 days/week).

interventionWe administered three weight-adjusted vaporised cannabis flower preparations: 'THC' (8 mg THC for 75 kg person); 'THC + CBD' (8 mg THC and 24 mg CBD for 75 kg person); and 'PLA' (matched placebo). MEASUREMENTS: Primary outcomes were (i) subjective 'feel drug effect'; (ii) verbal episodic memory (delayed prose recall); and (iii) psychotomimetic effect (Psychotomimetic States Inventory).

findingsCompared with 'PLA', 'THC' and 'THC + CBD' significantly (P < 0.001) increased 'feel drug effect' (mean difference [MD] = 6.3, 95% CI = 5.3-7.2; MD = 6.8, 95% CI = 6.0-7.7), impaired verbal episodic memory (MD = -2.7, 95% CI = -4.1 to -1.4; MD = -2.9, 95% CI = -4.1 to -1.7) and increased psychotomimetic effects (MD = 7.8, 95% CI = 2.8-12.7; MD = 10.8, 95% CI = 6.2-15.4). There was no evidence that adolescents differed from adults in their responses to cannabis (interaction P ≥ 0.4). Bayesian analyses supported equivalent effects of cannabis in adolescents and adults (Bayes factor [BF

conclusionsAdolescent cannabis users are neither more resilient nor more vulnerable than adult cannabis users to the acute psychotomimetic, verbal memory-impairing or subjective effects of cannabis. Furthermore, in adolescents and adults, vaporised cannabidiol does not mitigate the acute harms caused by delta-9-tetrahydocannabinol.

Indexed as

CannabidiolCannabisHallucinogensMarijuana SmokingAdolescentAdultBayes TheoremCannabinoid Receptor AgonistsCross-Over StudiesDouble-Blind MethodDronabinolFemaleHumansCannabidiolCannabinoid Receptor AgonistsDronabinolHallucinogensadolescencecannabisCBDcognitionmemorypsychosissubjective drug effectsTHC

Identifiers

PMID36750134
PMCPMC10481756
OpenAlexW4319335998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.